Senior Research Assistant

Job description 

We are seeking a motivated Senior Research Assistant to contribute to engineering novel solutions and capabilities for our genome editing platform and their application for developing more efficient and safer cell & gene therapy technologies.

The candidate will participate in a highly translational project with interactions with key partners in the advance therapy field.

Expected starting date: January 2026.

Information on the requirements 

• MSc in biology, biomedicine, biotechnology, genetics, or other relevant experimental or health sciences.
• Relevant molecular and/or cell biology laboratory experience (3 year minimum).
• Previous experience in mammalian cell culture and transfection, FACS analysis, gene editing or genome engineering, synthetic gene engineering, molecular cloning, or next generation sequencing will be highly valued.
• Interest in applied genetic engineering and synthetic biology.
• Curiosity and motivation to learn new techniques and protocols.
• Good time management and communication skills.
• Excellent team player who enjoys working in a fast-evolving research environment.

Benefits of the opening

The candidate will receive a full-time contract, and competitive annual fixed salary according to the merits and experience of the candidate. She/he will be able to receive adequate training and career growth plan. 
 

Application process: 

Please send the following documents:

• CV (Name_Surname_CV.pdf)
• Cover letter (Name_Surname_CL.pdf)

To the email address info@integra-tx.com  with “Senior_RA_application” in the email title.

Confidentiality in document handling and equality of opportunities policy are guaranteed by Integra Therapeutics.

About Integra

Integra Therapeutics is a biotechnology company that is creating next-generation gene writing tools to make advanced therapies safer and more effective. The technology is based on the CRISPR system, which has been merged with transposase and integrase proteins that have a great capacity for gene transfer. Thus, the system does not depend on viral vectors for transporting the gene-editing components into the cell both ex vivo and in-vivo.

The company was founded in 2020 as a spin-off of Pompeu Fabra University (UPF) by Dr Marc Güell and Dr Avencia Sánchez-Mejías and is based in  Barcelona. It is supported by international investors (AdBio Partners, Columbus Venture Partners, Invivo Capital, Takeda Ventures, CDTI Innvierte and the EIC Fund) and organizations in the healthcare and biomedicine sector. More information: www.integra-tx.com